ArticleOncology letters2026
Establishment of extrahepatic bile duct cancer organoids using suspension culture and their application in clinical drug screening.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aims to explore the feasibility of establishing human extrahepatic cholangiocarcinoma (eCCA) organoids via suspension culture, to biologically characterize their biological features and to evaluate their drug sensitivity, thereby providing a preclinical model for personalized precision therapy. Surgically resected tumor tissues were obtained from patients with eCCA. Tumor cells were isolated by mechanical dissociation and enzymatic digestion, and were cultured in a matrix-free suspension system for three-dimensional organoid formation and continuous passaging. Histomorphological features of the organoids and the corresponding parental tumor tissues were compared by H&E staining. Immunohistochemistry was used to detect the expression of the cholangiocyte markers cytokeratin (CK)7 and CK19, as well as Ki-67, to confirm tissue origin and proliferative activity. In addition, the organoid model was used for
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.